Trial Data Show STK-001 Safe, Likely Effective at Reducing Seizures

Trial Data Show STK-001 Safe, Likely Effective at Reducing Seizures

313022

Trial Data Show STK-001 Safe, Likely Effective at Reducing Seizures

Stoke Therapeutics’ investigational therapy STK-001 is generally safe and results in a trend toward a reduction in seizure frequency in children and adolescents with Dravet syndrome, according to interim data from the ongoing Phase 1/2a MONARCH trial. These promising early findings, concerning STK-001’s single doses up to 30 mg and multiple doses at 20 mg, supported a decision from the U.S. Food and Drug Administration (FDA) allowing the evaluation of an additional higher dose —…

You must be logged in to read/download the full post.